Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1 by Gifford, Robert J. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phylogenetic surveillance of viral genetic diversity and the
evolving molecular epidemiology of human immunodeficiency
virus type 1
Citation for published version:
Gifford, RJ, de Oliveira, T, Rambaut, A, Pybus, OG, Dunn, D, Vandamme, A-M, Kellam, P, Pillay, D & UK
Collaborative Grp HIV Drug 2007, 'Phylogenetic surveillance of viral genetic diversity and the evolving
molecular epidemiology of human immunodeficiency virus type 1' Journal of Virology, vol 81, no. 23, pp.
13050-13056., 10.1128/JVI.00889-07
Digital Object Identifier (DOI):
10.1128/JVI.00889-07
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher final version (usually the publisher pdf)
Published In:
Journal of Virology
Publisher Rights Statement:
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium,
provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
Vol. 24 no. 1 2008, pages 34–41
BIOINFORMATICS ORIGINAL PAPER doi:10.1093/bioinformatics/btm540
Sequence analysis
Estimation of an in vivo fitness landscape experienced by
HIV-1 under drug selective pressure useful for prediction of
drug resistance evolution during treatment
K. Deforche1, R. Camacho2, K. Van Laethem1, P. Lemey1,3, A. Rambaut4,
Y. Moreau5 and A.-M. Vandamme1,*
1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium, 2Centro Hospitalar de Lisboa
Ocidental, Lisbon, Portugal, 3Department of Zoology, Oxford University, Oxford, 4Institute for Evolutionary Biology,
University of Edinburgh, Edinburgh, UK and 5ESAT, Katholieke Universiteit Leuven, Leuven, Belgium
Received on January 4, 2007; revised on October 19, 2007; accepted on October 22, 2007
Advance Access publication November 17, 2007
Associate Editor: Burkhard Rost
ABSTRACT
Motivation: HIV-1 antiviral resistance is a major cause of antiviral
treatment failure. The in vivo fitness landscape experienced by the
virus in presence of treatment could in principle be used to determine
both the susceptibility of the virus to the treatment and the genetic
barrier to resistance. We propose a method to estimate this fitness
landscape from cross-sectional clinical genetic sequence data of
different subtypes, by reverse engineering the required selective
pressure for HIV-1 sequences obtained from treatment naive patients,
to evolve towards sequences obtained from treated patients. The
method was evaluated for recovering 10 random fictive selective
pressures in simulation experiments, and for modeling the selective
pressure under treatment with the protease inhibitor nelfinavir.
Results: The estimated fitness function under nelfinavir treatment
considered fitness contributions of 114 mutations at 48 sites. Estimated
fitness correlated significantly with the in vitro resistance phenotype in
519 matched genotype-phenotype pairs (R2¼0.47 (0.410.54)) and
variation in predicted evolution under nelfinavir selective pressure
correlated significantly with observed in vivo evolution during nelfinavir
treatment for 39 mutations (with FDR ¼ 0.05).
Availability: The software is available on request from the authors,
and data sets are available from http://jose.med.kuleuven.be/
kdforc0/nfv-fitness-data/.
Contact: annemie.vandamme@uz.kuleuven.be
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
HIV antiviral drugs interfere with viral proteins resulting in the
inhibition of HIV replication. In many cases, HIV escapes the
inhibition of these drugs by selection of drug resistance
mutations, leading to treatment failure (Vandamme, 1999). To
combine drugs in an effective treatment therefore requires taking
into account the presence of resistance mutations, and resistance
testing has become a standard of care (Vandamme et al., 2004).
Different viral mechanisms may be distinguished that affect
short-term versus long-term response to antiviral treatment.
In addition to the impact of other factors such as adherence,
potency of therapy and pharmacokinetics, the short-term
response to treatment is mainly determined by the susceptibility
of the virus to the drugs. In the long-term, susceptible virus may
evolve to acquire resistance mutations, and the expected time
needed for the virus to evolve the necessary resistance mutations
is related to the number of nucleotide substitutions required,
which can be quantified as the genetic barrier. Several
bioinformatics methods have been used successfully in the field
of antiviral drug resistance, including methods that predict
in vitro phenotypic resistance from the genetic sequence, and
methods that describe qualitative relationships between different
mutations selected during treatment (Beerenwinkel et al.,
2005b). Recently, these techniques were combined to compare
the genetic barrier for individual drugs versus drug combinations
(Beerenwinkel et al., 2005c).
Due to technical shortcomings, problems with the interpreta-
tion of the results, and the lack of a genetic barrier concept, in
vitro phenotypic assays display limitations in their capacity of
predicting therapy outcome (Van Laethem and Vandamme,
2006). Therefore, the usefulness of machine-learning
approaches to predict resistance phenotype from genotype
may be limited. On the other hand, the success of attempts to
directly learn genotypic patterns responsible for reduced
treatment response from clinical data has been limited by the
lack of sufficient data, and the confounding effect of many other
factors (DiRienzo and DeGruttola, 2002). The in vivo fitness of
the virus in presence of treatment, which reflects both effects
of drug resistance and replication capacity,1 determines the
immediate treatment response, but cannot be measured directly.
*To whom correspondence should be addressed.
1In this article, the universal meaning of fitness as the capacity to
replicate in a given environment is used, rather than as a synonym for
replication capacity in a drug-free environment as is often the case in
the HIV drug resistance community.
 2007 The Author(s)
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However, HIV tries to recover its ability to replicate
efficiently in presence of treatment by accumulating resistance
mutations, thus exploring sequence space in the immediate
neighborhood of the current sequence. Therefore, observed
evolution in clinical sequences at treatment failure provides
information about the fitness landscape, but only in the
immediate neighborhood of the current sequence. In this
article, we present a method to reverse engineer this fitness
landscape experienced by HIV-1 in presence of treatment as a
function of the genetic sequence, from observed selection
during treatment in clinical sequences. The method searches for
a fitness landscape, which explains how an observed population
of treated sequences could have evolved from a population of
untreated sequences under selective pressure. After showing
that random, but known fitness functions could be successfully
estimated in this way, we applied the method to model the
fitness landscape of HIV-1 in presence of the protease inhibitor
(PI) nelfinavir (NFV).
2 MATERIALS AND METHODS
2.1 Clinical data set
To estimate the fitness function under NFV selective pressure, clinical
data was pooled from the Stanford HIV Drug Resistance Database
(Kantor et al., 2001), from the University Hospitals, Leuven, Belgium,
and from Hospital Egas Monis, Lisbon, Portugal, to create a treated
population PT of 1026 sequences from patients with experience to NFV
as sole PI, and a naive population PN of 7774 sequences from PI naive
patients. At most one treated and one naive sequence per patient was
used, and duplicate sequences (that were present in the hospital
database but also published in the Stanford database) were identified
and removed. The treated population consisted mostly of HIV-1
subtype B sequences, but included also a large number of subtype G
and subtype C sequences (Fig. 1), as determined from the protease and
partial reverse transcriptase sequences using the REGA HIV-1 Subtype
tool v2.0 (de Oliveira et al., 2005). Nucleotide ambiguities that occur
commonly in the population sequences were resolved by randomly
substituting the mixture with a suitable pure nucleotide. Using a
threshold of 0.5% prevalence at variable sites, 114 mutations at 48
protease positions were included in the fitness function models, and are
listed in Supplementary Material A. To remove redundancy, the most
prevalent mutation at each position was considered the ‘wild type’ and
was omitted from the fitness function model, as its presence was implied
in the absence of any mutation.
2.2 Method to estimate a fitness function
We present a method with objective to learn a function F(A1, . . . , An),
where Ai presents presence or absence of a mutation, that represents the
fitness landscape of HIV under drug selective pressure. To learn F, we
find a function that fits with the evolution of the virus in a naive
population of patients PN to a treated population PT, and is closest to
neutrality (minimizing |F 1|). The fitness function F incorporates
interactions indicated using Bayesian Network (BN) learning, and its
parameters are estimated using an iterative procedure where evolution
for PN over the current fitness function estimate is simulated, and
compared to PT.
2.2.1 Fitness function structure The protease amino acid sequen-
ces from the treated population PT were used to learn interactions
between mutations as described before (Deforche et al., 2006).
Briefly, a data set was created where a boolean variable indicated the
presence of each included mutation. BN structure learning (Myllyma¨ki
et al., 2002) on this boolean data was used to discover relationships
between these mutations that may indicate epistatic fitness effects. By
assuming conditional independencies, the Bayesian Network refactors
the Joint Probability Distribution (JPD) in a product of Conditional
Probability Distributions (CPD), leading to a reduction in number of
parameters to model the JPD. Formally, for n variables A1, . . . ,An
(representing amino acid mutations), we would write:
PðA1; . . . ;AnÞ ¼
Yn
i
PðAi j parents ðAiÞÞ
with P(A |B) the conditional probability of A given B, and parents (Ai)
the parents in the BN structure of variable Ai. We denote the most
probable network of the amino acid sequences of the treated population
PT with structure ST and CPD parameters T as BNT(T, ST).
We model the relative fitness function F(A1, . . . , An) in the same way
as BNT(T, ST) refactors the JPD:
FðA1; . . . ;AnÞ ¼
Yn
i
FðAi j parents ðAiÞÞ
with parents (Ai) the parents in S
T, and F(A |B) the Conditional Fitness
Contribution (CFC) of the presence of A, depending on the presence of
B. The assumption here is that if two mutations are synergistic for
example, they would occur more often together than not, and a
dependency should be visible in the JPD too. See Supplementary
Material B for an example.
The CPDs are modeled by specifying the probability for a mutation
Ai given any pattern of parent mutations k, in Conditional Probability
Tables (CPTs): i,k ¼ P(Ai ¼ 1| parents(Ai) ¼ k). Similarly, we used
Conditional Fitness Tables (CFTs) to model the CFCs for each
mutation Ai, which specify a different fitness contribution of the
presence of a mutation Ai for every pattern of parent mutations: i,k ¼
F(Ai ¼ 1| parents(Ai) ¼ k).
2.2.2 Model of evolution Both for estimating the fitness function
parameters, and for prediction of sequence evolution during treatment,
the same stochastic model of HIV evolution was used. Evolution was
considered as an accumulation of fixations of nucleotide mutations in
the HIV intra-host population, as reflected in the consensus sequence,
under the selective pressure of an arbitrarily complex fitness function.
This corresponds roughly to how HIV resistance evolution is observed
in population sequences obtained by genotypic resistance tests (Van
Laethem and Vandamme, 2006).
The HIV intra-host population was modeled by a finite ideal Wright–
Fisher population with selection andmutation, using empirical estimates
of the HIV intra-host effective population size, mutation rate and
B
G
C
Other
Unknown
Fig. 1. HIV-1 subtype distribution of NFV treated population. Other
subtypes were mostly CRFs. Sequences whose subtype could not be
determined either because they were recombinant, or because only the
protease was available were classified as Unknown.
In vivo fitness landscape modeling HIV-1 drug resistance
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mutation rate biases derived from literature, and selection coefficients
derived from the fitness function F. Analytical results lack for fixation
time distributions of mutations in the Wright–Fisher model for all but
the simplest cases (Ewens, 1979). Therefore, to sample from these distri-
butions, for a Wright–Fisher model with multiple loci and a complex
fitness function with epistatic interactions, an approximate simulation of
this model was implemented. For a detailed description of the imple-
mented model and approximations see Supplementary Material C.
2.2.3 Fitness function parameters The parameters i, k of the
function F are estimated so that evolution over the fitness landscape of a
naive population PN resembles the treated population PT. Therefore,
evolution is simulated for sequences sampled from the naive population
PN using the fitness function, to obtain an evolved population PE. The
difference between the sequence populationsPE andPT, whichmust thus
be minimized, is measured by comparing the parameters of BNT(T, ST)
of the treated data set, with BNE(E, ST), a BN estimated from the
simulated population using the structure that was learned from the
treated data set. Thus, we measure and minimize the difference in
prevalence of eachmutational pattern that is modeled by the BN, and for
which the fitness function specifies a separate fitness contribution.
Given this minimization objective, the parameters i, k are not
necessarily unique, since we cannot quantify how unfit unobserved
mutational patterns are. Indeed, we can only determine how unfit these
patterns must be at least to explain their lack of evolution. We constrain
the search to a unique solution by minimizing |i, k  1 | for each
parameter i, k, as a secondary objective (with a low weight compared to
the first objective).
An iterative algorithm was used to estimate the parameters. The
algorithm starts initially from a flat fitness function (i.e. F(A1, . . . , An)
¼ 1), and in each iteration this function is updated in a step-wise
fashion. A population PE is computed using the current estimate of the
fitness function F. The fitness function parameters i,k are subsequently
adjusted based on the difference in the sufficient statistics (which reflect
the counts) related to the BN parameters Ei; k and 
T
i; k: i, k is increased
with a small multiplicative factor (1þ i,k) when there is too few of
mutation Ai for parent combination k in the evolved versus treated
population, or vice versa if there is too much of mutation Ai. By using
the sufficient statistics instead of the actual CPD parameters, uncer-
tainty on these parameters is taken into account. The step sizes i, k are
dynamically adjusted depending on the convergence of the correspond-
ing i, k. Details, pseudo-code, and convergence properties of the
algorithm are presented in Supplementary Material D.
The amount of evolution experienced by HIV under treatment
depends on many factors such as the baseline viral load, the potency of
the combination therapy to suppress residual replication (which
depends on the amount of resistance), patient adherence and duration
of the therapy. The probability distribution for the effective number of
generations under drug pressure between sequences from drug naive
and treated patients P(GT), which is used to create PE, is in general
unknown and was assumed to be uniform in the interval [0, Gmax], with
Gmax a maximum limit for the number of generations. Variation of Gmax
does not affect the shape of the landscape, but its steepness (lower
values result in a steeper landscape).
2.2.4 Phylogenetic guide tree The sampling of sequences from
PN was guided by a phylogenetic tree, and more weight was given to
sequences from the naive population that were epidemiologically linked
to the treated population. This assures that the sampled population had
a similar epidemiological background to the treated population
avoiding that mutations linked to epidemiologies with a different
distribution among these population were assigned as arising during
treatment [an improvement compared to stratifying according to
epidemiology (Deforche et al., 2006; Kantor et al., 2006)]. The protease
and partial reverse transcriptase nucleotide sequences were used to
reconstruct a neighbor-joining phylogenetic tree including all naive and
treated isolates used in the training data. The tree was built using PAUP
(Swofford, 2000) using the HKY- substitution model, and codons
representing IAS resistance associated positions (Johnson et al., 2005)
were excluded to avoid problems of convergent evolution.
Each sequence nT from the treated population PT added a
contribution k e r d(nT, nN) to the sampling weight of a sequence nN,
with d (n1, n2) the tree distance between two taxa n1 and n2, r a decay
factor and k a normalizing coefficient so that
P
nN ke
rd ðnT; nNÞ ¼ jPTj1.
2.2.5 Constants For the HIV simulation model, a constant intra-
patient effective population size Ne¼ 104 was assumed, a value
previously estimated from in vivo observations during treatment
(Nijhuis et al., 1998; Rouzine and Coffin, 1999), and an average
mutation rate  ¼ 2.17105 mutations/site/generation (Mansky and
Temin, 1995) was used. Furthermore, we used base-dependent mutation
rates i ¼ (bfrom, bto) that were estimated from in vivo longitudinal
data (Deforche et al., 2007). For the estimation, we used Gmax ¼ 200,
corresponding to about a year of evolution, given an estimated
generation turnover time of  1.5 days; LE ¼ |PE | ¼ 10  |PT |
and  ¼ 10 7.
2.3 Validation experiments
2.3.1 Correlation with nelfinavir resistance phenotype Using a
public data set of matched genotype–phenotype pairs for subtype B
sequences [from the Stanford HIV Drug Database (Kantor et al.,
2001)], estimated fitness was compared to in vitro resistance fold change
phenotype. Sequences with unknown amino acid mutations (‘Z’ or ‘X’)
were removed, as were sequences with a fold change at the upper
detection range of the assay. For each of the remaining 519 amino acid
sequences j, fitness f^j was estimated from resistance fold change Rj,
using (Holford and Sheiner, 1982):
f^j ¼ ej
1þ DRj
with ej the replication capacity of the virus and D the effective drug
concentration. The values ej are generally unknown, and ej ¼ 1 was
assumed for all strains when computing f^j. The fitness estimated from
the phenotypes was then compared with the fitness computed using the
estimated fitness landscape by computing the correlation coefficient,
which was indifferent to the value of D.
2.3.2 Correlation with observed nelfinavir resistance
evolution In 404 patients for which a baseline and consecutive
follow-up sequence during NFV treatment was available, the accuracy
of the model to predict observed resistance evolution was evaluated.
These pairs were independent from the cross-sectional training data. For
each wild type and mutation included in the fitness function, correlation
of observed evolution (0 or 1) with predicted evolution (05p51) was
evaluated. Correlation with observed evolution was analyzed with a
linear model, which included next to the predicted evolution a non-linear
correction for the number of observed substitutions for each sequence.
Correction for multiple testing was done using the Benjamini and
Hochberg method with FDR = 0.05. An observed mixture (such as
L63LPA) was evaluated against predicting evolution of the mutations
(for this example L63P or L63A). Prediction of loss of mutations in
mixtures (such as LPA63P) was not considered.
3 RESULTS
3.1 Simulation experiments
To illustrate convergence properties of the method, the method
was tested in two series of simulation experiments: (i) to recover
K.Deforche et al.
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10 random but known fitness functions for HIV, each
corresponding to a random fictive selective pressure on
protease, and (ii) to re-estimate the fitness function that was
estimated for HIV in presence of NFV, from four training data
sets of varying size.
Each of the 10 random fitness functions used the same 114
mutations as those considered for the NFV fitness function
(listed in Supplementary Material A), and was generated with
100 random interactions (BN arcs), and random fitness
contributions for presence of different mutations and patterns
of mutations sampled from the distribution 1þU(0, 1)6. For
each random fitness function, a training data set of 1000
sequences was generated by evolving PI naive sequences using
the fitness function for g generations, sampled from distribu-
tion P(GT). Similarly, the estimated NFV fitness function was
used to create training data sets of size 513, 1026, 2052 and
10 260. The generated training sequences together with the PI
naive sequences were then used to estimate the original
(random or estimated NFV) fitness function.
A weight w was defined for each arc in a random BN as the
change in likelihood of that BN in the corresponding generated
data set, when removing the arc, and reflects the strength of the
interaction in the generated sequences. For around 60% of
arcs, a value of w51 indicated that the implied interaction was
not considered during evolution. These arcs were in general not
present in the learned BN. Of arcs with w41, over 60% were
present in the learned BN, with higher probability for arcs with
higher w. Around 12% of arcs in the learned BNs indicated the
obvious antagonism between different mutations at a single
position (a consequence of the chosen data representation), and
other artefact arcs mostly indicated associations between
polymorphisms. The accuracy of the estimated fitness functions
was evaluated by correlation of known and estimated fitness for
1000 independent validation sequences that were generated in
the same way as the training data. Results were similar for the
random and estimated NFV fitness functions. Correlation
coefficients showed considerable variation with values for R2
between 0.47 and 0.84 (see Supplementary Material E). Low
correlation values were associated with a banding pattern in the
scatter plots. When adding subtype as an explanatory variable
to the linear regression, these banding patterns disappeared,
and correlation improved with R2 ranging between 0.79 and
0.94. This indicates that the estimated fitness landscapes
performed well to explain intra-subtype variation of fitness
under treatment, but not inter-subtype variation, which is
indeed not related to fitness changes under treatment.
3.2 Nelfinavir fitness function
3.2.1 Nelfinavir Bayesian network A BN was estimated
from the treated sequences to estimate epistatic fitness
interactions between the included mutations. The network
with highest a posteriori probability, that served as a blueprint
for the fitness function, included 271 arcs (of which 33 indicated
antagonisms between different mutations at a single position,
which is an artifact caused by the boolean data representation),
and the corresponding fitness interactions were included in the
fitness model. The network was similar to the one described
previously (Deforche et al., 2006), but here we allowed for more
putative interactions because no bootstrap procedure was run
to reduce the entire model. Bootstrap support for an arc reflects
the robustness of the arc against sampling effects in the data set,
and is only important when inferring conclusions from the
presence or absence of arcs.
3.2.2 Nelfinavir fitness function By comparing the PI naive
population with the NFV treated population, the parameters
for the fitness function during NFV treatment were estimated
using the iterative procedure described in Methods section, and
using a phylogenetic guide tree to correct for different
epidemiology of naive and treated viruses.
The fitness function modeled contributions and epistatic
interactions of well-described resistance mutations. For exam-
ple, in absence of the well-described D30N major resistance
mutation, the model predicted no contribution of the N88D
mutation to fitness under NFV selective pressure. In presence
of a D30N mutation, the model predicted a contribution of
58% for N88D, and in presence of both D30N and V77I, a
contribution of 75%.
3.2.3 Correlation with in vitro resistance phenotype Correla-
tion with in vitro resistance fold change data for NFV was
investigated for 519 sequences (not included in the training data
set), assuming no effects of replication capacity and a constant
drug concentration. The log estimated in vitro fitness showed a
reasonable correlation with the log estimated in vitro fitness
(R2¼ 0.47 (0.41 0.54), p510 15, Fig. 2) with no clear trend
in the differences.
3.2.4 Correlation with observed evolution The ability of the
model for evolution using the estimated fitness function, to
predict observed evolution during NFV treatment, was evalu-
ated by comparing predicted evolution with observed evolution
in 404 patients treated with NFV. In Figures 3–6 the predicted
evolution is shown for some examples of sequences from patients
for which the prediction was in agreement with observed
evolution, meaning the observed sequence after NFV failure
was the sequence with the highest predicted probability
compared to the other probable sequences of the same
generation. These graphs illustrate variation in prediction,
caused by variability in baseline sequence. In Table 1, the
mutations were listed for which variation in predicted evolution
showed a significant positive correlation with observed evolu-
tion, after correcting for multiple testing. Negative correlations
were not found for any mutation, and thus we made no overall
wrong predictions. For some patients under NFV treatment,
only minor (or secondary mutations) (Shafer, 2002) were
predicted and observed in the virus, in absence of any major
mutation. This may provide an explanation why the initial
classification of primary and secondary mutations were unten-
able (now major and minor) since in reality for some patients
secondary mutations were observed first.
4 DISCUSSION
4.1 Estimating in vivo fitness during treatment
In this study, we presented a computational method to estimate
the in vivo fitness function of HIV-1 during treatment. The
In vivo fitness landscape modeling HIV-1 drug resistance
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estimated fitness landscape reflects the selective pressures on
HIV to evolve the necessary mutations to explain the change in
prevalence of single mutations or patterns of mutations in HIV
isolated from patients failing a specific treatment, compared to
treatment naive sequence data. The estimation follows two
consecutive steps. First, epistatic fitness interactions between
mutations are estimated. Since an interaction between two
mutations is expected to lead to a different observed prevalence
of one mutation depending on the presence of the other,
observed associations in prevalence may indicate such fitness
interactions. BN learning was used to search for interactions
between mutations as described in Deforche et al. (2006). These
interactions were included in a multiplicative fitness function
(Sanjuan et al., 2004), which describes fitness as a product of
independent contributions of presence of amino mutations,
augmented with independent contributions for combinations of
interacting mutations. Second, the fitness contributions were
estimated using an iterative procedure so that simulated
evolution over the fitness landscape of treatment naive
sequences resulted in sequences comparable to the sequences
from treated patients. Therefore, the fitness function models the
part of sequence space bounded by these circulating sequences
and does not extrapolate to sequences that are not observed in
the epidemic, and for which there is little interest in an
improved resistance interpretation.
The estimation was not based on in vitro experimental data,
such as resistance fold change assays and fitness assays, or on
in vivo correlates of viral fitness such as viral load, but instead
was estimated from observed evolution in clinical sequences.
Fitness was estimated based on the evolutionary principle that
substitutions observed in the consensus sequence of a popula-
tion under strong selective pressure are mostly fixed to increase
the fitness of the population. As such, the increase in prevalence
of a particular mutation in the population of sequences after
NFV failure, compared to the population of sequences that
were NFV naive, reflects the consecutive fixation of mutations
in a population that acquires increased fitness under NFV
selective pressure. Not only increase in prevalence of individual
mutations was considered, but also of patterns of mutations,
since epistatic fitness interactions alter the fitness impact of
mutations depending on a context of other mutations. The
fitness model included n-ary epistatic effects, which were
estimated using BN structure learning that has demonstrated
its ability to learn epistatic interactions between different
protein residues in general (Klingler and Brutlag, 1994) and
applied to HIV drug resistance mutations in particular
(Deforche et al., 2006).
Experiments with random fitness landscapes showed that the
method, at least within the assumptions of the model, could be
used to accurately estimate intra-subtype variation in fitness,
but in general does not allow learning of inter-subtype
variation. This may be explained by the fact that the method
relies on observed evolution to distinguish less fit and more fit
mutational patterns. Even if, for example, subtype C viruses
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Fig. 3. Predicted evolution graph for a subtype B sequence (bold). Each
node corresponds to a sequence that is predicted to evolve from the
baseline sequence with the estimated probability given. An arc from
sequence X to sequence Y corresponds to a mutation with given
probability to evolve sequence X into sequence Y. Only sequences with
predicted probability p40.05 are shown. For this baseline sequence,
evolution of mutations D30N M36I was observed during NFV
treatment, corresponding to the predicted sequence with two mutations
with highest probability (dashed).
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Fig. 2. Estimating the in vivo fitness of HIV-1 during NFV treatment.
Comparison of estimated fitness from in vitro phenotypic resistance
data for 519 matched genotype–phenotype pairs, assuming no effects of
replication capacity and effective drug concentration D¼ 100.
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Fig. 4. Predicted evolution graph for a subtype B sequence (bold), for
which evolution of mutation V77I was observed during NFV treatment
(dashed). Legend as in Figure 3.
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would be less susceptible to NFV treatment, and therefore more
fit under treatment, a subtype B virus will never evolve to
become subtype C. Since only intra-subtype evolution under
drug selective pressure is observed, the method cannot estimate
the fitness impact of conserved patterns of polymorphisms in
different subtypes that are responsible for the fitness difference.
This explains the nature of the shifted bands in the scatter plots
(Figs 1 and 3 in Supplementary Material E), which disappear
when adding subtype into the linear regression model (Figs 2
and 4 in Supplementary Material E). Still, the method will use
differences in observed evolution under treatment in different
subtypes, to model fitness interactions between some of these
polymorphisms and certain resistance pathways.
Since fitness during treatment depends on the susceptibility of
the virus to the drug, the fitness estimate can be considered an
in vivo resistance phenotype, and should therefore correlate with
the in vitro resistance phenotype. While the correlation was
found to be highly significant (Fig. 2), discordance was higher
than with the random fitness landscapes. Uncertainty about
parameters, assumptions and simplifications made by the model
may explain part of the observed discordance. However, in this
evaluation we may question which one is the better estimate, our
computational approach taking into account only in vivo
parameters, or the in vitro phenotypic data. One could argue in
favor of the in vivo estimate, since the in vitro data suffers from
problems with the in vitro resistance assays, such as the
reproducibility at low fold changes, recombination artifacts
intrinsic for the recombinant virus assays used, replication
capacity of the recombinant virus, and other possible artifacts
from the in vitro test environment. The in vivo estimate on the
other hand, while based on indirect information, does take into
account the influence of replication capacity, and interaction
with the immune system through epitopes.
As a model for evolution in the HIV intra-host population, an
ideal Wright–Fisher model was assumed, seeded with empirical
parameters for HIV intra-host evolution from literature. The
model however did not include recombination, assumed a
constant population size and no other effects of selection besides
the treatment-related fitness function. Each of these assumptions
baseline + L23I
0.05
baseline + M89I
0.05
baseline + M89I L90M
0.08
L90M
(0.11)
I13V K14R K20I E35D M36I
S37N R41K H69K V82I L89M
L23I
(0.05)
M89I
(0.05)
baseline + L90M
(0.23)
L90M
(0.23)
baseline + I62V
(0.05)
I62V
(0.05)
baseline + I54V
(0.06)
I54V
(0.06)
baseline + D35N
(0.12)
D35N
(0.12)
M89I
(0.31)
baseline + I54V L90M
(0.06)
I54V
(0.21)
L90M
(0.20)
Fig. 5. Predicted evolution graph for a subtype G sequence (bold), for which evolution of mutations M89I L90M was observed during NFV
treatment (dashed). Legend as in Figure 3.
Table 1. Predicted mutations during NFV treatment
m N n p m N n p
10F 390 17 1.11E–04 57R 50 7 1.28E–09
10V 388 11 2.21E–02 62V 322 42 4.56E–07
13V 283 34 8.89E–14 63P 133 27 4.38E–03
15V 331 18 4.68E–02 64V 329 22 5.30E–07
20I 356 13 2.56E–08 70R 390 7 1.75E–04
20R 388 12 2.37E–07 71T 366 27 7.45E–03
20T 387 15 8.92E–07 71V 332 37 6.37E–07
20V 402 4 2.53E–09 74S 378 21 7.68E–04
30N 317 55 5.01E–07 77I 277 31 1.27E–05
33F 396 5 3.12E–02 82A 369 11 1.45E–07
33I 400 5 5.30E–17 85V 395 6 6.67E–07
35D 254 29 1.26E–04 88D 355 39 8.95E–12
35N 398 6 9.29E–16 88S 391 16 3.20E–02
36I 262 32 2.78E–04 89I 394 7 1.08E–11
36V 390 7 7.68E–03 89L 74 2 1.15E–02
39S 396 2 8.12E–10 89V 397 3 4.73E–03
45R 389 9 3.00E–02 90M 325 59 1.14E–07
46I 361 41 4.73E–04 92K 400 5 3.98E–02
46L 376 15 1.29E–02 93L 262 23 1.50E–04
54V 369 10 2.37E–03
Mutations for which predicted variation in rate of selection, based on the genetic
context, correlated significantly with observed selection in patients during NFV
treatment (FDR = 0.05). N: the number of baseline sequences without the
mutation, of which n developed the mutation during treatment. p: P-value for
correlation between predicted probability for selection of the mutation and
observed selection, after correcting for multiple comparison with Benjamini and
Hochberg.
T12S M36I S37N R41K
H69K L89M I93L
0.08
E35D M36I S37N R41K
H69K L89M I93L
0.11
E35D M36I S37N R41K
L63P H69K L89M I93L
0.07
L63P
(0.22)
M36I S37N R41K H69K
L89M I93L
T12S
(0.08)
E35D
(0.11)
M36I S37N R41K L63P
H69K L89M I93L
0.28
L63P
(0.28)
M36I S37N R41K I62V
H69K L89M I93L
0.05
I62V
(0.05)
E35D
(0.15)
M36I S37N R41K I62V
L63P H69K L89M I93L
0.05
I62V
(0.13)
L63P
(0.34)
Fig. 6. Predicted evolution graph for a subtype C sequence (bold),
for which evolution of mutations E35D L63P was observed during
NFV treatment (dashed). Legend as in Figure 3.
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are unlikely for HIV and this will impact the accuracy of the
estimated fitness landscape.Moreover, analytical results lack for
fixation time distributions in a Wright–Fisher model. An
accurate implementation of this model therefore requires a full
simulation, which was avoided because of the high computa-
tional cost, through several approximations that are detailed in
Supplementary Material C. Because the estimate was optimized
to predict evolution, however, the accuracy of predicted
evolution should be less affected (since the fitness function will
be distorted to predict observed evolution with an approximate
evolutionary model). These simplifications and approximations,
including the lack of recombination in the model, may be
avoided with availability of a more accurate, but also more
computationally demanding simulator.
4.2 Predicting evolution during treatment
The fitness landscape together with the evolution simulator
were used to predict evolution during treatment, and depending
on variation in the baseline sequences (presence of polymorphic
and resistance mutations), variation in rate of selection of
mutations was predicted that correlated significantly with
observed variation in selection for 39 mutations (Table 1).
The predictability of selection of a mutation that is more
prevalent in isolates after treatment implies the involvement of
that mutation in improving fitness in the presence of treatment.
However, a mutation whose selection does not depend on
genetic context may equally well be an important resistance
mutation, while such a mutation would not yield any predictable
variation of selection for thatmutation. Therefore, predictability
should not be interpreted as a quantification of the fitness gain.
For example, a common polymorphism such as I64V for which
there were 22 occurrences was about as significantly predicted as
L90M (which is non-polymorphic) for which there were 59
occurrences. This only indicates that selection of I64V is more
dependent on the genetic background than L90M. The 39
mutations included most of the described NFV resistance
mutations (Johnson et al., 2005): 10F, 30N, 36I, 46I/L, 71T/V,
77I, 82A, 88D/S and 90M. In addition, there were a number of
resistance mutations that have not been associated with NFV
but with other protease inhibitors: 10V, 13V, 20I/R, 33I/F, 36V,
54V, 62V, 63P, 85V and 93L, including mutations that have been
described only for the more recently introduced PIs atazanavir
or tipranavir (such as 13V, 20I, 33I/F, 36V, 62V, 85V and 93L).
These novel protease inhibitors may require more mutations
before losing clinical utility, but seem to be affected by the same
set of mutations that are selected by older inhibitors such as
NFV, and therefore cross-resistance may be underestimated.
For these novel mutations that are often selected and well
predicted, such as 13V, 35D, 62V, 64V or 93L, the fitness
landscape contains knowledge about the genetic context that
influences the fitness contributions of these mutations. This
knowledge could be used for further investigation of the
biological role and mechanism through in vitro mutagenesis
experiments.
A convenient representation of HIV resistance evolution is as
a probabilistic-ordered accumulation of resistance mutations.
Such models has been inferred previously from cross-sectional
data (Beerenwinkel et al., 2005), describing evolution starting
from a ‘wild-type’ sequence. We extended this approach by
creating individualized evolution graphs that predict evolution
for any sequence (Figs 3–6), wild type of whatever subtype or
recombinant, or partially resistant sequences that just enter
higher in the landscape. The examples illustrate how variation
in wild-type HIV-1 sequences influences the predicted evolu-
tion, for some sequences major or primary mutations arising
first, and for other sequences first minor or secondary
mutations, all in an ordered stochastic but predictable fashion.
Our predictions imply that resistance evolution is highly
individual, depending on the baseline sequence of the virus,
and thus could be used for guiding individualized treatment
choices. For example, the evolution graph in Figure 6 implies
a higher predicted genetic barrier, in expected number of
mutations before becoming resistant, than the evolution graph
in Figure 5, under the assumption that mutations E35D and
L63P do not cause resistance to NFV (Van Laethem et al.,
2002).
The technique presented here was developed to particularly
take into account the large natural diversity of HIV-1, and
estimates a fitness landscape that may be used across subtypes.
As further discussed in Supplementary Material F, no assump-
tions were made about wild type and mutation (a common
source for a subtype bias when using the subtype B reference
strain), and the method deals in a natural way with sequences
from other subtypes that have polymorphisms that are
considered resistance mutations in a subtype B genetic environ-
ment (such as M36I in subtype C). Since access to antiviral
medication is expanding beyond patients infected with HIV-1
subtype B, which is the most prevalent subtype in the Western
World but almost absent in other parts of the world, resistance
development in other subtypes requires more attention.
4.3 Related work and other applications
Beerenwinkel et al. (2005c) used a combination of phenotypic
data and a model of ordered resistance evolution learned from
cross-sectional data to estimate the genetic barrier against
zidovudine and lamivudine. A Poisson process for selection
of mutations was assumed to derive the expected selection
time from the observed selection probabilities along the
branches of mutagenic trees. Each mutagenic tree defines
possible evolutionary pathways on a lattice structure
(Beerenwinkel et al., 2005a) and the informative trees in the
mixture therefore constrain evolution a priori. In contrast, we
did not constrain evolution according to a limited number of
pathways, but let an evolutionary model, using the shape of the
fitness landscape, decide the probabilities of selecting particular
mutations.
While the method for estimating a fitness function was
developed to obtain a better understanding in HIV drug resis-
tance evolution with the objective of improving prediction of
treatment response, it could be applied to other selective pre-
ssures for HIV (such as adaptation to immune response) or
other organisms. The main requirement is that convergent
evolution is observed in a number of isolated populations exp-
eriencing the same selective pressure. This makes the technique
particularly well suited for fast evolving viruses, which by
their nature form relatively isolated intra-host populations.
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Other than genotypic sequence data, the method requires
estimates of effective population size and mutation rates.
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